BeiGene Report Results of Brukinsa (zanubrutinib) in P-III ASPEN Study for Waldenström’s Macroglobulinemia

 BeiGene Report Results of Brukinsa (zanubrutinib) in P-III ASPEN Study for Waldenström’s Macroglobulinemia

BeiGene Report Results of Brukinsa (zanubrutinib) in P-III ASPEN Study for Waldenström’s Macroglobulinemia

Shots:

  • The P-III APSEN study involve assessing of Brukinsa (zanubrutinib) vs AbbVie’s Imbruvica (ibrutinib) in 229 patients with r/r or TN WM across 61 centers in the US, EU and Australia
  • The P-III APSEN study resulted in not meeting its 1EPs, i.e, superiority in CR & VGPR rate in up to 3yrs.; in r/r patients & overall patient population: VGPR rate (28.9% & 28.4% vs 19.8% & 19.2%); MRR (78.3% & 77.5% vs 80.2% & 77.8%); PFS @12mos. (92.4% & 85.9% vs 89.7% & 87.2%); OS @12mos. (98.8% & 92.5% vs 97.0% & 93.9%); safety profile were similar; respectively
  • Brukinsa (BGB-3111) is a BTK inhibitor, currently being evaluated in multiple clinical studies globally including China as a potential monothx. or in combination with other therapies targeting B cell malignancies

Click here ­to­ read full press release/ article | Ref: BeiGene | Image: USCA

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post